There are no contraindications for pembrolizumab.

Limitations of use:

- Pembrolizumab is not recommended in PMBCL (primary mediastinal large B-cell lymphoma) patients who require urgent cytoreductive therapy.

- Pembrolizumabâ€™s safety and effectiveness in MSI-H central nervous system pediatric cancer have not been established as this population met the exclusion criteria from clinical trials.